SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Follow-Up Questions
Who is the CEO of Sellas Life Sciences Group Inc?
Dr. Angelos Stergiou is the President of Sellas Life Sciences Group Inc, joining the firm since 2017.
What is the price performance of SLS stock?
The current price of SLS is $1.61, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Sellas Life Sciences Group Inc?
Sellas Life Sciences Group Inc belongs to Biotechnology industry and the sector is Health Care
What is Sellas Life Sciences Group Inc market cap?
Sellas Life Sciences Group Inc's current market cap is $169.5M
Is Sellas Life Sciences Group Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Sellas Life Sciences Group Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
